Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.123.267297 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Mélanie Desaulniers und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada; melanie.desaulniers2@usherbrooke.ca. Hauptthemen laut MEDLINE: Synovitis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Radiosynoviorthesis is approved in several European countries and the United States to treat refractory synovitis in many inflammatory joint diseases, such as rheumatoid arthritis, spondyloarthropathies, and other arthritic joint diseases. No radiopharmaceuticals for radiosynoviorthesis are currently approved in Canada. The aim of this Health Canada-approved trial was to demonstrate the safety and efficacy of radiosynoviorthesis.
Methods
Between July 2012 and November 2017, we conducted a multicenter, prospective, interventional Canadian trial. Patients (n = 360) with synovitis refractory to standard treatments after failing 2 intraarticular glucocorticoid injections were included. They were followed up at 3, 6, and 12 mo. Outcome measures included adverse events (AEs) and clinical signs of synovitis (pain, swelling, and joint effusion) measured with the Health Assessment Questionnaire Disability Index, the Disease Activity Score, and the Visual Analog Scale.
Results
In total, 392 joints were treated, including those reinjected after 6 mo (n = 34). Of these, 83.4% (327/392) were injected with [90Y]Y-citrate for the knees and 9.9% (39/392) with [186Re]Re-sulfide for medium-sized joints. Of the joints treated, 82.7% (324/392) were knees. Fifty-five AEs, most of them of mild grade, occurred and resolved without sequelae and were not life-threatening. The incidence of radiosynoviorthesis-related AEs was 9.4% (34/360). The proportion of patients showing an improvement in synovitis symptoms after radiosynoviorthesis was significant at 3 mo and was maintained up to 12 mo (P < 0.001).
Conclusion
This study confirmed the safety of radiosynoviorthesis in the treatment of patients with synovitis refractory to standard treatments. There is evidence of sustained clinical efficacy at 12 mo, suggesting that radiosynoviorthesis is an effective treatment for improving synovitis symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada; melanie.desaulniers2@usherbrooke.ca.
- Research Center of CHUS, CIUSSSE-CHUS, Sherbrooke, Quebec, Canada.
- Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
- Arthritis Program Research Group Inc., Newmarket, Ontario, Canada.
- Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada; and.
- Division of Rheumatology, Southlake Regional Health Center, Newmarket, Ontario, Canada.
Zitieren
APA
Desaulniers, M., Paquette, M., Dubreuil, S., Senta, H., Lavallée, É., Thorne, J. C., & Turcotte, É. (2024). Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.267297
Vancouver
Desaulniers M, Paquette M, Dubreuil S, Senta H, Lavallée É, Thorne JC, et al. Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.267297
BibTeX
@article{Desaulniers2024,
author = {Desaulniers, Mélanie and Paquette, Michel and Dubreuil, Stéphanie and Senta, Helena and Lavallée, Éric and Thorne, J Carter and Turcotte, Éric},
title = {Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.123.267297}
}
EUVIMED